Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2010 by AIDS Healthcare Foundation.
Recruitment status was:  Recruiting
Ganeden Biotech, Inc.
Information provided by:
AIDS Healthcare Foundation Identifier:
First received: August 17, 2010
Last updated: NA
Last verified: August 2010
History: No changes posted

Improvement in the rate of bacterial translocation may lead to a decrease in a chronic inflammatory response thereby decreasing CD4 destruction and HIV proliferation.

By the addition of probiotics we hope to show a reduction in LPS leading to a decrease in chronic inflammation and therefore an improvement in immune markers.

Condition Intervention Phase
HIV Infection
Gastrointestinal Symptoms
Dietary Supplement: GanedenBC30, GBI-30, PTA-6086
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System

Resource links provided by NLM:

Further study details as provided by AIDS Healthcare Foundation:

Primary Outcome Measures:
  • Safety [ Time Frame: 30, 60, and 90 days. ]
    Assess adverse events.

Secondary Outcome Measures:
  • Improvement in CD4 cell counts. [ Time Frame: 90 days. ]
    Laboratory blood tests of CD4 lymphocytes.

  • Improvement of gastrointestinal symptoms. [ Time Frame: 30, 60, and 90 days. ]
    Measure improvement in GSRS questionnaire scores.

Estimated Enrollment: 24
Study Start Date: August 2010
Estimated Study Completion Date: July 2011
Estimated Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GanedenBC30, GBI-30, PTA-6086 Dietary Supplement: GanedenBC30, GBI-30, PTA-6086
1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.
Other Names:
  • Bacillus coagulans
  • Probiotics
Placebo Comparator: Placebo Drug: Placebo
1 capsule per day for 90 days.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient is male or non-pregnant, non-lactating female.
  • Adults 18 years or older.
  • Is able to provide written, informed consent to participate in the study.
  • Serological documentation of HIV infection at any time prior to study entry and is clinically stable.
  • Stable CD4 count greater than or equal to 250 cells/cubic mm for six months prior to study entry (+/- 50 cells/cubic mm).
  • HIV-1 RNA ≤50 copies/mL for six months prior to study entry.
  • Karnofsky performance status - 60%.
  • Adequate laboratory parameters within the last 30 days:

    1. absolute neutrophil count >1000 cells/cubic mm
    2. hemoglobin >9.0 g/dL
    3. platelets >75,000/cubic mm
    4. creatinine <1.5 x upper limit of normal
    5. SGOT/SGPT <3.0 x upper limit of normal
    6. bilirubin <2.0 mg/dL
  • Patients with documented GI symptoms to include but are not limited to: flatulence, diarrhea, bloating, gastroesophageal reflux disease, nausea, and constipation.
  • If females are of childbearing potential, they must be practicing an effective method of contraception and agree to use birth control while on protocol and for 1 month after completion of study. Women of Child Bearing Potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to start of study medication. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not. postmenopausal [defined as amenorrhea for 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL]. Even women who are using oral, implanted or, injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential.
  • Must agree to practice protected sexual activity (via barrier method) during course of the study.
  • In the opinion of the investigator, is willing and able to comply with the study requirements.

Exclusion Criteria:

  • Active opportunistic infection, which is progressive, or imminently disabling or life threatening, in the judgment of the Principal Investigator with exception of Kaposi Sarcoma.
  • Cytotoxic chemotherapy, interferon treatment, or radiation therapy within the preceding 3 weeks (subjects who have received intralesional chemotherapy will not be excluded, however).
  • Any antibiotic therapy within 30 days of enrollment
  • Any probiotic formulation within 30 days of enrollment
  • Any immunization within 30 days of enrollment
  • Known history of allergic reactions to any of the investigational products or their ingredients.
  • Chronic treatment with immunosuppressant drugs, including corticosteroids, except for the treatment of adrenal insufficiency. Topical steroids are permitted.
  • History of or known current malabsorption syndrome.
  • Any grade 3 or 4 lab abnormalities as defined by a standardized grading scheme based on the DAIDS table (see Appendix B) with the following exceptions:
  • Pre-existing diabetes with glucose toxicity elevations ≥ grade 3
  • Triglyceride or total cholesterol elevations ≥ grade 3
  • Clinical or laboratory evidence of clinically significant liver impairment/ dysfunction, disease or cirrhosis.
  • Life expectancy < 6 months in the opinion of the investigator.
  • Active substance abuse or significant psychiatric illness that in the opinion of the investigator might interfere with study compliance.
  • Female subject of childbearing potential not using effective non-hormonal birth control methods or not willing to continue practicing these birth control methods from screening until the last trial related activity.
  • Subject is pregnant or lactating.
  • Any condition that in the Principal Investigator's opinion may render the subject unable to complete the study or which may pose significant risk to the subject.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01184456

United States, California
AHF Research Center Recruiting
Beverly Hills, California, United States, 90211
Contact: Robert Cordova, RN,BSN,CCRP    323-913-1033   
Principal Investigator: Homayoon Khanlou, MD         
Sponsors and Collaborators
AIDS Healthcare Foundation
Ganeden Biotech, Inc.
  More Information

Responsible Party: Robert Cordova, AIDS Healthcare Foundation Identifier: NCT01184456     History of Changes
Other Study ID Numbers: AHF-GAN01
Study First Received: August 17, 2010
Last Updated: August 17, 2010

Keywords provided by AIDS Healthcare Foundation:
Acquired Immunodeficiency Syndrome
Human Immunodeficiency Virus

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases processed this record on April 28, 2017